Khalafallah Alhossain, Grabek Julian, Hayes Robert, Mohamed Muhajir
Department of Haematology, Launceston General Hospital, Tasmania, Australia.
BMJ Case Rep. 2013 Aug 6;2013:bcr2013010018. doi: 10.1136/bcr-2013-010018.
An 85-year-old man on warfarin for atrial fibrillation presented with skin bleeding. International normalised ratio (INR) and activated partial thromboplastin time (APTT) were elevated and did not correct even after warfarin reversal with vitamin K, prothrombin complex concentrate (PCC) and fresh frozen plasma. Mixing coagulation studies with normal plasma suggested the presence of an inhibitor rather than the multiple coagulation factor deficiencies expected with warfarin. Assays of the common-pathway coagulation factors revealed factor V concentration <2% with inhibitor level elevated to 11 Bethesda units. The bleeding resolved following a course of corticosteroids. Coagulation studies and factor V level returned to normal along with resolution of the inhibitor. We report the case of the diagnostic dilemma posed and successful therapy implemented despite the limited evidence-based data being available for the treatment of this rare condition.
一名85岁因心房颤动服用华法林的男性出现皮肤出血。国际标准化比值(INR)和活化部分凝血活酶时间(APTT)升高,即使使用维生素K、凝血酶原复合物浓缩物(PCC)和新鲜冰冻血浆逆转华法林后仍未恢复正常。与正常血浆进行的混合凝血试验提示存在抑制剂,而非华法林所致的多种凝血因子缺乏。对共同途径凝血因子的检测显示,因子V浓度<2%,抑制剂水平升高至11贝塞斯达单位。经皮质类固醇治疗后出血症状缓解。随着抑制剂的消退,凝血试验和因子V水平恢复正常。我们报告了这一病例,尽管针对这种罕见疾病的治疗缺乏足够的循证数据,但仍成功解决了诊断难题并实施了治疗。